March 17, 2010
Putting a Dollar Figure on a Doctor’s Worth to a Hospital
In an article posted on the WSJ Health Blog, James A. White asks and answers the following questions:
What’s a doctor worth to a hospital in terms of annual revenue? And what specialties average the most and the least in hospital revenue generation? The answer to the first question averages about $1.54 million a year, based on 114 U.S. hospital responding to a survey by physician recruiters Merritt Hawkins. That’s up slightly from the $1.5 million a year per doc that hospitals averaged in revenue in 2007, the last time the recruiting outfit took the survey. (Revenue here means net inpatient and outpatient dollars derived from referrals, tests and procedures done in the hospital.)
Merritt Hawkins also asked about revenue generation in the last 12 months by 17 doctor specialties. Not all 114 hospitals replied for all specialists but below are the averages for the responses received. Also included is a list of average annual salaries that came from other Merritt Hawkins data:
Hospital Annual Revenue per Doctor by Specialty
|Specialty||Avg. Revenue||Avg. Salary|
Top 10 Papers on SSRN for Journal of Public Health Law and Policy
January 16, 2010 to March 17, 2010
March 15, 2010
Conflicts of Interest in Clincial Trial Recruitment & Enrollment: A Call for Increased Oversight
A White Paper called Conflicts of Interest in Clincial Trial Recruitment & Enrollment: A Call for Increased Oversight by The Center for Health & Pharmaceutical Law & Policy at Seton Hall Law School (Kathleen M. Boozang, Carl H. Coleman, Tracy E. Miller, Kate Greenwood, Valerie Gutmann, Simone Handler-Hutchinson, and Catherine Finizio) has been posted on SSRN. The abstract reads:
This White Paper makes several policy recommendations to eliminate or manage the conflicts of interest that arise pursuant to the compensation arrangements between investigators and their institutions with drug and medical device manufacturers as they affect the recruitment and enrollment of human research subjects in clinical trials. The paper seeks to accomplish overall financial neutrality as between treatment and research, so that physicians' decisions regarding inclusion of patients in clinical trials is unaffected by their own financial interests.
Nano Luggage Designed to Carry Therapeutic Agents to Diseased Cells
For the first time, scientists have fully emptied the Cowpea mosaic virus of its genetic material rendering it non-infectious. Particles of the virus can now be used as nano luggage that carries therapeutic agents directly to diseased cells. The paper entitled Cowpea Mosaic Virus Unmodified Empty Virus-Like Particles Can Be Loaded with Metal and Metal Oxide was published in the specialized nanotechnology journal Small. A ScienceDaily article explains the implications of this research:
[S]cientists have succeeded in growing empty particles derived from a plant virus and have made them carry useful chemicals. The external surface of these nano containers could be decorated with molecules that guide them to where they are needed in the body, before the chemical load is discharged to exert its effect on diseased cells. The containers are particles of the Cowpea mosaic virus, which is ideally suited for designing biomaterial at the nanoscale.
Scientists have previously tried to empty virus particles of their genetic material using irradiation or chemical treatment. Though successful in rendering the particles non-infectious, these methods have not fully emptied the particles.
One application could be in cancer treatment. Integrins are molecules that appear on cancer cells. The virus particles could be coated externally with peptides that bind to integrins. This would mean the particles seek out cancer cells to the exclusion of healthy cells. Once bound to the cancer cell, the virus particle would release an anti-cancer agent that has been carried as an internal cargo. Some current drugs damage healthy cells as well as the cancer, leading to hair loss and other side effects. This technology could deliver the drug in a more targeted way.